◼ Archived
Business
Merck, Daiichi pull lung cancer filing after FDA pushback deals another blow to $4B deal
Merck and Daiichi Sankyo pull their US lung cancer drug application following regulatory pushback.
3 trends tracked about this subject — the full history, oldest to newest below.
Merck and Daiichi Sankyo pull their US lung cancer drug application following regulatory pushback.
A new modular in vivo antibody-ADC click chemistry approach aims to reverse drug resistance in tumors, including pancreatic cancer.
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.